The Future of Precision Cancer Care is Here.
What We DoEliminating Uncertainty, Individualizing Care
At SimBioSys, we are determined to deliver on the promise of precision cancer care by combining the power of science and software into a first-of-its kind biophysical simulation technology to:
- Give physicians the ability to better predict response to therapy during treatment planning to individualize treatment selection, enabling improvement in outcomes while lowering toxicity for patients
- Provide patients and physicians with a platform for shared decision making and collaboration, transforming patient experience
- Identify novel and actionable insights capturing the impact of drug delivery, metabolism, spatial heterogeneity and physical traits, expediting the drug development process
Our Solutions
For Clinicians
To empower clinicians with individualized treatment planning tools
For Life Sciences
To arm drug developers with novel biomarkers, patient stratification, clinical trial selection and design strategies
News and Resources
2022 Best Tech Startups in Champaign
SimBioSys is one of the 2022 best tech startups in Champaign! "The Tech Tribune staff has compiled the very best tech startups in Champaign, Illinois. In doing our research, we considered several factors...
SimBioSys to Showcase Latest Research on TumorScope at ASCO 2022
CHICAGO – JUNE 3, 2022 -- SimBioSys, the technology company that predicts tumor responses to therapy, announced today it will showcase research at the American Society of Clinical Oncology (ASCO) Annual...
SimBioSys Presents 9 Applications of TumorScope Platform at AACR 2022
The company’s first appearance at this prestigious cancer research conference profiles use cases of platform for cancer treatment planning and as a cancer research tool.
Biopharma Dealmakers: Virtualizing cancer to eliminate uncertainty and individualize care
No two tumors are alike. What if we could model treatment planning for each individual patient? Meet TumorScope – the first of its kind 4D Tumor Modeling platform that combines state of the art biophysical...
Harnessing the immune system to develop breakthrough cancer therapies
By: Matthew Biancalana Antibodies are the immune system’s targeted defense system, known best for their ability to selectively pinpoint pathogens and mark them for destruction. The last decade in cancer care...
Takeaways from ESMO 2022
By: Anuja Antony and Dorys Lopez Our chief medical officer, Dr. Anuja Antony, represented SimBioSys at the ESMO 2022 conference last month. Among the many exciting advances and developments in the breast...
Enabling personalized cancer care through AI and computer simulations with NVIDIA
By: Joseph R. Peterson and Dorys Lopez From Precision Medicine to Personalized Medicine No two tumors are alike. Despite some tumors sharing the same biological characteristics, inter-patient heterogeneity...
Huge ASCO Breakthroughs: But will these Innovations Advance Equitable Cancer Care?
By Dorys Lopez Our team was present at the American Society of Clinical Oncology (ASCO) annual meeting that took place from June 3 – 7, 2022. Perhaps the most impactful moment for breast cancer oncologists...